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To the Editor:
The evidence-based clinical prac-
tice guideline on molecular testing for 
the selection of lung cancer patients 
for epidermal growth factor recep-
tor (EGFR) and anaplastic lymphoma 
kinase tyrosine kinase inhibitors by the 
College of American Pathologists, the 
International Association for the Study 
of Lung Cancer, and the Association 
for Molecular Pathology recommends 
that patients with lung adenocarcinoma 
should not be excluded from testing 
based on clinical characteristics that 
include ethnicity, smoking history, and 
sex.1 We totally agree with this rec-
ommendation as our experience and 
findings also show that sex and smok-
ing history are not sensitive or specific 
enough to exclude individual patients 
from testing even though in our patients, 
EGFR mutations were more frequent in 
women (52.5%) than in men (27.8%) 
and more frequent in never smokers 
(54.8%) than in ever smokers (20.7%).2
EGFR mutations are rare in well-
characterized, fully excised surgical 
specimens of squamous cell lung car-
cinoma lacking any adenocarcinoma 
component with a reported frequency 
of less than 5%.1 In the case of limited 
lung cancer specimens by small biopsies 
where the possibility of an adenocarci-
noma component cannot be completely 
excluded, the guideline recommends 
that EGFR mutation testing may be per-
formed in cases showing squamous cell 
histology with clinical characteristics 
such as young age and a lack of smok-
ing history.1 From our experience with 
small biopsy specimens taken during 
flexible bronchoscopy or transcuta-
neous needle biopsy in patients with 
advanced-stage non–small-lung can-
cer, EGFR mutations were detected 
with the use of real-time polymerase 
chain reaction based on Scorpion® and 
Amplification Refractory Mutation 
System® technologies in 39.4% of ade-
nocarcinoma from 132 patients whereas 
only one (9.1%) of 11 squamous cell 
carcinomas was EGFR-mutation posi-
tive. The only EGFR-mutation–positive 
squamous cell carcinoma was from a 
never smoker whereas the squamous 
cell carcinomas from all 10 smokers 
were EGFR-mutation negative.3
Other expert panels4 recommend 
that apart from nonsquamous NSCLC, 
EGFR mutation testing should be per-
formed in squamous cell carcinoma 
patients with clinical features associ-
ated with higher prevalence of EGFR 
mutations such as a lack of smoking 
history. Furthermore, adenosquamous 
carcinomas and solid adenocarcinomas, 
in which EGFR mutations have been 
reported, can mimic squamous cell car-
cinoma in small biopsy specimens.5 
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To the Editor:
We read with great interest the 
article published by Errihani et al. on 
the spectrum of epidermal growth factor 
receptor (EGFR) mutation in Moroccan 
patients (n = 137) with lung adenocar-
cinoma (AC), and we would like to con-
gratulate them for their very important 
study which in our knowledge represent 
the first study in Morocco and Arab 
population.
In Morocco, lung cancer represents 
the first cause of cancer in men1,2 and the 
ninth cause of cancer in women.2 AC is 
the second most common histological 
subtype after squamous-cell carcinoma 
according to the Casablanca registry, rep-
resenting 26% of all lung cancers (24.7% 
in men and 36.9% in women [most com-
mon histology in women]).2
The authors showed that the 
overall frequency of the EGFR muta-
tion was 21%, which is higher than 
that in white population (11%–
13.7%).3–6 Mutations were mainly 
detected in the exon 19 (69%), fol-
lowed by exon 21 (21%) and exon 
20 (7%), whereas mutations in the 
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exon 18 were rare (3%) in concor-
dance with the majority of published 
studies.3,4,6 In addition, the authors 
confirmed the Asian and occidental 
conclusions that EGFR mutation rate 
was significantly higher in women 
and in never smokers.3,4,6
However, the study presents sev-
eral limitations because of numerous 
biases, and the result presented here 
should be interpreted with caution3:
- The population analyzed was 
not representative for the overall 
Moroccan population; as an exam-
ple, the frequency of EGFR muta-
tion in female patients included 
was 34% (46 of 137), largely higher 
than frequencies showed in Rabat 
and Casablanca registries (the only 
2 registries available in Morocco).1,2 
According to Casablanca registry, 
women with AC represent only 
16% of lung AC and men with AC 
represent 84% of lung AC.1 In fact, 
in Morocco women, lung cancer 
was a relatively rare condition rep-
resenting only 8% to 11.5% of all 
lung cancers versus 33.4% in devel-
oped countries.1,2,7,8 And women 
with lung cancer in Morocco are 
not smoker in the vast majority of 
the case (79%).7
- In another hand, the analysis was 
performed according to specimen 
available in private laboratories 
(Nations-Unies Pathology Center, 
Hassan Pathology Center, and 
Agdal Pathology Center, at Rabat, 
Morocco; and Casapath Pathology 
Center at Casablanca, Morocco.) 
excluding the majority of speci-
men available at the most important 
institutions in Morocco, such as 
the University Hospitals (National 
Institute of Oncology at Rabat, 
Morocco, and Ibn-Rochd University 
Hospital at Casablanca, Morocco).
We do not agree with the author’s 
conclusion that EGFR mutation fre-
quency in Moroccan patients is higher 
than that found in whites, but it is 
the same than that observed in white 
population. By using the frequency 
of EGFR mutation in men (7 of 91 
= 7.7%) and the frequency of EGFR 
mutation in women (22 of 46 = 47.8%) 
calculated from data of the present 
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article and by using Moroccan sta-
tistics (Casablanca registry), we can 
estimate the true frequency of EGFR 
mutation in our population; according 
to Casablanca registry (the most pow-
erful registry), female patients with 
lung AC represent 16% of lung AC 
and male patients with lung AC rep-
resent 84% of lung AC, the frequency 
of EGFR mutation will be approxi-
mately (16 × 47.8/100 + 7.7 × 84/100 
= 7.6% + 6.45%) = 14%. Therefore, 
we suggest that the incidence of 
EGFR mutation in Moroccan patients 
is equivalent than that observed in 
white population, and we encourage 
the Moroccan investigators to conduct 
a multiinstitutional and large study 
including consecutive patients with 
AC diagnosed at the most important 
Cancer Center in Morocco to confirm 
this suggestion and to refine the result 
of the present study.3 
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In Response:
On behalf of the author group, we 
thank Dr. Ismaili for his interest in our 
article Spectrum of EGFR Mutation in 
Lung Adenocarcinoma in Morocco1 and 
his insightful comments.
With regard to his comments, we 
think the following points should be 
clarified. First, our series was a retro-
spective study and therefore some poten-
tial sources of bias cannot be ruled out. 
Despite this, our results provide some 
information about the frequency of epi-
dermal growth factor receptor (EGFR) 
mutation in lung adenocarcinoma in 
Morocco, and as indicated in our article, 
have to be confirmed in larger prospec-
tive studies. Second, data analysis was 
performed according to the availability 
of specimens in private pathology labora-
tories because these laboratories perform 
more than 90% of all tests requested in 
Morocco, and EGFR mutation testing is 
not available for specimens that could be 
found in public institutions.
We do not fully agree with sug-
gestion made by Dr. Ismaili that the inci-
dence of EGFR mutation in Moroccan 
patients would be equivalent than that 
observed in white population. In our 
series, the EGFR mutation rate was 
higher than that found in other studies 
conducted in whites despite similar sex 
distribution.2,3 For example, Rosell et 
al.2, in a large prospective Spanish study, 
reported EGFR mutation in only 16% 
of patients with lung cancer including 
39% of female patients. In such situa-
tion, extrapolation as done by Dr. Ismaili 
should be avoided, and we believe that the 
best way to provide an accurate EGFR 
mutation rate in Moroccan patients is to 
